<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Bartholomew, John R.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Thrombosis and Anticoagulation: Essentials for the General Cardiologist</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">25-27</style></pages><abstract><style  face="normal" font="default" size="100%">Deep vein thrombosis (DVT) occurs in approximately 2 million Americans each year. Nearly 600,000 of these patients will develop a pulmonary embolism (PE), and almost 60,000 will die of this complication [Hirsh H &amp; Hoak J. Circulation 1996]. The goal of antithrombotic therapy for venous thromboembolic (VTE) disease is the prevention of clot propagation, embolism, and recurrent thrombosis. This article reviews the 2008 ACCP evidence-based clinical practice guidelines regarding VTE disease, which established new strategies for the treatment of acute DVT and PE [Chest 2008;133 (6 suppl)].</style></abstract><number><style face="normal" font="default" size="100%">2</style></number><volume><style face="normal" font="default" size="100%">9</style></volume></record></records></xml>